These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 26519380

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Update on the pharmacotherapy of cerebellar and central vestibular disorders.
    Kalla R, Teufel J, Feil K, Muth C, Strupp M.
    J Neurol; 2016 Apr; 263 Suppl 1():S24-9. PubMed ID: 27083881
    [Abstract] [Full Text] [Related]

  • 3. Aminopyridines and Acetyl-DL-leucine: New Therapies in Cerebellar Disorders.
    Kalla R, Strupp M.
    Curr Neuropharmacol; 2019 Apr; 17(1):7-13. PubMed ID: 30182858
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacotherapy of vestibular and cerebellar disorders and downbeat nystagmus: translational and back-translational research.
    Strupp M, Zwergal A, Feil K, Bremova T, Brandt T.
    Ann N Y Acad Sci; 2015 Apr; 1343():27-36. PubMed ID: 25903394
    [Abstract] [Full Text] [Related]

  • 6. Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial.
    Feil K, Adrion C, Teufel J, Bösch S, Claassen J, Giordano I, Hengel H, Jacobi H, Klockgether T, Klopstock T, Nachbauer W, Schöls L, Stendel C, Uslar E, van de Warrenburg B, Berger I, Naumann I, Bayer O, Müller HH, Mansmann U, Strupp M.
    BMC Neurol; 2017 Jan 10; 17(1):7. PubMed ID: 28068987
    [Abstract] [Full Text] [Related]

  • 7. [Pharmacotherapy of Vestibular Disorders, Nystagmus and Cerebellar Disorders].
    Feil K, Böttcher N, Kremmyda O, Muth C, Teufel J, Zwergal A, Brandt T, Strupp M.
    Fortschr Neurol Psychiatr; 2015 Sep 10; 83(9):490-8. PubMed ID: 26421856
    [Abstract] [Full Text] [Related]

  • 8. [Pharmacotherapy of Vestibular Disorders, Nystagmus and Cerebellar Disorders].
    Feil K, Böttcher N, Kremmyda O, Muth C, Teufel J, Zwergal A, Brandt T, Strupp M.
    Laryngorhinootologie; 2018 Jan 10; 97(1):14-23. PubMed ID: 29301160
    [Abstract] [Full Text] [Related]

  • 9. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus.
    Kalla R, Glasauer S, Büttner U, Brandt T, Strupp M.
    Brain; 2007 Sep 10; 130(Pt 9):2441-51. PubMed ID: 17664175
    [Abstract] [Full Text] [Related]

  • 10. Effect of chlorzoxazone in patients with downbeat nystagmus: a pilot trial.
    Feil K, Claaßen J, Bardins S, Teufel J, Krafczyk S, Schneider E, Schniepp R, Jahn K, Kalla R, Strupp M.
    Neurology; 2013 Sep 24; 81(13):1152-8. PubMed ID: 23975871
    [Abstract] [Full Text] [Related]

  • 11. The role of regularity and synchrony of cerebellar Purkinje cells for pathological nystagmus.
    Glasauer S, Rössert C, Strupp M.
    Ann N Y Acad Sci; 2011 Sep 24; 1233():162-7. PubMed ID: 21950989
    [Abstract] [Full Text] [Related]

  • 12. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
    Alviña K, Khodakhah K.
    J Neurosci; 2010 May 26; 30(21):7258-68. PubMed ID: 20505092
    [Abstract] [Full Text] [Related]

  • 13. Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2--a video case report.
    Löhle M, Schrempf W, Wolz M, Reichmann H, Storch A.
    Mov Disord; 2008 Jul 15; 23(9):1314-6. PubMed ID: 18442126
    [Abstract] [Full Text] [Related]

  • 14. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.
    Hess E.
    Neurology; 2011 Nov 29; 77(22):1996-7; author reply 1997. PubMed ID: 22123782
    [No Abstract] [Full Text] [Related]

  • 15. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.
    Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T.
    Neurology; 2004 May 11; 62(9):1623-5. PubMed ID: 15136697
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus.
    Kalla R, Spiegel R, Claassen J, Bardins S, Hahn A, Schneider E, Rettinger N, Glasauer S, Brandt T, Strupp M.
    J Neuroophthalmol; 2011 Dec 11; 31(4):320-5. PubMed ID: 21734596
    [Abstract] [Full Text] [Related]

  • 19. Safety and Efficacy of Acetyl-DL-Leucine in Certain Types of Cerebellar Ataxia: The ALCAT Randomized Clinical Crossover Trial.
    Feil K, Adrion C, Boesch S, Doss S, Giordano I, Hengel H, Jacobi H, Klockgether T, Klopstock T, Nachbauer W, Schöls L, Steiner KM, Stendel C, Timmann D, Naumann I, Mansmann U, Strupp M, ALCAT Study Group.
    JAMA Netw Open; 2021 Dec 01; 4(12):e2135841. PubMed ID: 34905009
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological advances in the treatment of neuro-otological and eye movement disorders.
    Strupp M, Brandt T.
    Curr Opin Neurol; 2006 Feb 01; 19(1):33-40. PubMed ID: 16415675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.